MMD’s Cardizem CD
Gains FDA approval for treatment of angina, Marion Merrell Dow reports Oct. 15. Once-daily formulation of diltiazem was approved in December 1991 for hypertension. Supplement for the angina indication was filed in January 1992 and around that time company officials predicted Cardizem CD might have "eventual" sales potential of more than $400 mil. ("The Pink Sheet" Jan. 13, p. 7). Sales for the Cardizem line topped $900 mil. in 1991.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth